Global Disposable Incontinence Products Market Is Expected to Reach USD 18.59 billion by 2027 : Fior Markets
October 12, 2020 22:00 ET
|
Fior Markets
Newark, NJ, Oct. 12, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, the global disposable incontinence products market is expected to grow from USD 10.42 billion in 2019 and...
Aravive Announces Initiation of Investigator-Sponsored Phase 1/2 Study of AVB-500 in Combination with Avelumab in Patients with Advanced Urothelial Carcinoma (COAXIN)
March 24, 2020 08:00 ET
|
Aravive, Inc.
HOUSTON, March 24, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that the first patient has been dosed in an investigator-sponsored...
CicloMed Presents New Oncology Data from Phase I Trial with Fosciclopirox at 2020 ASCO Genitourinary Cancers Symposium
February 13, 2020 09:15 ET
|
CicloMed LLC
First-time results from recently completed fosciclopirox Phase I safety, dose tolerance, pharmacokinetics and pharmacodynamics trial in advanced solid-tumor patientsInitiation of fosciclopirox...
Streetwise Reports Publishes 'Two Analysts See Company as a Buy for 'Game-Changing' Potential in Bladder Cancer Detection and Surgery'
January 15, 2020 07:00 ET
|
Streetwise Reports Llc
SAN FRANCISCO, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Imagin Medical Inc. (IME:CSE; IMEXF:OTCQB) is developing technology that can greatly improve the ability to visualize cancer during minimally...
CicloMed Expands Fosciclopirox Phase 1 Trial to Include Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Patients
December 03, 2019 09:30 ET
|
CicloMed LLC
KANSAS CITY, Mo., Dec. 03, 2019 (GLOBE NEWSWIRE) -- CicloMed LLC, a biotechnology company developing novel treatments for bladder cancer, today announced the expansion of its fosciclopirox clinical...
Le 5e cancer le plus courant au Canada classé au 21e rang au niveau du financement de la recherche - Aidez-nous dès aujourd’hui et ravivez l’espoir des Canadiens touchés par le cancer de la vessie
August 27, 2019 14:53 ET
|
Bladder Cancer Canada
TORONTO, 27 août 2019 (GLOBE NEWSWIRE) -- Cette année, ce sont près de 9 000 Canadiens qui recevront un diagnostic de cancer de la vessie1. Bien qu’il s’agisse du 5e cancer le plus courant au...
Fifth most common cancer now ranked 21st in terms of cancer research funding - Your time to help is NOW!
August 27, 2019 14:53 ET
|
Bladder Cancer Canada
TORONTO, Aug. 27, 2019 (GLOBE NEWSWIRE) -- This year about 9,000 Canadians will be diagnosed with bladder cancer1. It’s the 5th most common cancer in Canada – yet many Canadians have never heard of...
Constellation Pharmaceuticals Presents Poster on Studies of CPI-0209 in Bladder Cancer at AACR Meeting
May 20, 2019 07:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., May 20, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that Dr. Patricia Keller, Senior Scientist at Constellation...
Cancer de la vessie Canada célèbre son 10e anniversaire
May 10, 2019 08:09 ET
|
Bladder Cancer Canada
TORONTO, 10 mai 2019 (GLOBE NEWSWIRE) -- Le 11 mai, il y a de cela 10 ans, deux survivants du cancer de la vessie — David Guttman et Jack Moon — ont pris des mesures qui auront une incidence...
Bladder Cancer Canada celebrates ten years
May 10, 2019 08:09 ET
|
Bladder Cancer Canada
TORONTO, May 10, 2019 (GLOBE NEWSWIRE) -- On May 11, ten years ago, two bladder cancer survivors – David Guttman and Jack Moon – took action that would positively impact countless Canadians. Seeing...